
    
      Pembrolizumab plus autologous dendritic cell vaccine in patients with PD-L1 negative advanced
      mesothelioma who have failed prior therapies.This is an exploratory, single-arm, open-label,
      phase 1b clinical trial.

      The study will explore treatment safety and the ability to induce PD-L1 expression of the
      study treatment. Secondary objective will include clinical activity and immunological
      efficacy.

      18 Patients will be enrolled . To ensure patients' protection and avoid unacceptable
      toxicity, a formal safety analysis will be conducted after six patients have been observed
      for at least 30 days after the third treatment cycle.

      The study will be conducted on PD-L1 negative advanced mesothelioma patients with progressive
      disease after standard therapy. Previous therapies must have included an antifolate agent and
      a platinum compound.

      Study treatment: Pembrolizumab 200 mg IV q3w until disease progression, unacceptable toxicity
      or informed consent withdrawal, or for a maximum of 2 years Autologous dendritic cells loaded
      with autologous tumor homogenate, 107 cells ID q3w for up to six doses Interleukin-2 3 MU
      s.c. from day +2 to day +6 after each DC administration.
    
  